当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2014年
13期
124-125
,共2页
信必可都保%孟鲁司特%稳定期%中重度%COPD
信必可都保%孟魯司特%穩定期%中重度%COPD
신필가도보%맹로사특%은정기%중중도%COPD
Budesonide and Formoterol Fum Arate Powder for Inhalation%Montelukast%Stable Phase%Moderate and Severe%COPD
目的:研究信必可都保以及孟鲁司特对稳定期的中重度慢性阻塞性肺疾病COPD疾病的疗效情况。方法2012年3月~2013年3月于广东省梅州市人民医院共计有86例患者被确诊为稳定期的中重度COPD疾病。以数字法随机均分成观察组(n=43)和对照组(n=43)。对比2组疗效以及不良反应情况。结果观察组治疗之后的FEV 1为(1.59±0.55)L、FEV 1%为(56.33±0.65)%,FEV 1/FVC为(61.95±0.45)%,均显著高于治疗之前的(1.46±0.42)L、(43.79±0.62)%、(52.64±0.45)%,以及对照组治疗之后的(1.46±0.67)L、(46.28±0.62)%、(56.74±0.51)%;观察组治疗之后的6-MWD为(226.08±18.5)m,显著大于治疗之前的(180.55±16.8)m,以及对照组治疗之后的(185.25±19.9)m;呼吸困难的评分为(2.05±0.62)分,均显著低于治疗之前的(3.04±0.24)分,以及对照组治疗之后的(2.97±0.58)分,差异均有统计学意义(均P<0.05)。治疗12周之后,观察组有2例口咽部不适,1例头痛,1例心悸;对照组1例口咽部不适,1例心悸。2组差异无统计学意义。结论信必可都保药物与孟鲁司特药物联用,加以治疗稳定期的中重度COPD疾病,疗效较为显著,值得临床推荐。
目的:研究信必可都保以及孟魯司特對穩定期的中重度慢性阻塞性肺疾病COPD疾病的療效情況。方法2012年3月~2013年3月于廣東省梅州市人民醫院共計有86例患者被確診為穩定期的中重度COPD疾病。以數字法隨機均分成觀察組(n=43)和對照組(n=43)。對比2組療效以及不良反應情況。結果觀察組治療之後的FEV 1為(1.59±0.55)L、FEV 1%為(56.33±0.65)%,FEV 1/FVC為(61.95±0.45)%,均顯著高于治療之前的(1.46±0.42)L、(43.79±0.62)%、(52.64±0.45)%,以及對照組治療之後的(1.46±0.67)L、(46.28±0.62)%、(56.74±0.51)%;觀察組治療之後的6-MWD為(226.08±18.5)m,顯著大于治療之前的(180.55±16.8)m,以及對照組治療之後的(185.25±19.9)m;呼吸睏難的評分為(2.05±0.62)分,均顯著低于治療之前的(3.04±0.24)分,以及對照組治療之後的(2.97±0.58)分,差異均有統計學意義(均P<0.05)。治療12週之後,觀察組有2例口嚥部不適,1例頭痛,1例心悸;對照組1例口嚥部不適,1例心悸。2組差異無統計學意義。結論信必可都保藥物與孟魯司特藥物聯用,加以治療穩定期的中重度COPD疾病,療效較為顯著,值得臨床推薦。
목적:연구신필가도보이급맹로사특대은정기적중중도만성조새성폐질병COPD질병적료효정황。방법2012년3월~2013년3월우광동성매주시인민의원공계유86례환자피학진위은정기적중중도COPD질병。이수자법수궤균분성관찰조(n=43)화대조조(n=43)。대비2조료효이급불량반응정황。결과관찰조치료지후적FEV 1위(1.59±0.55)L、FEV 1%위(56.33±0.65)%,FEV 1/FVC위(61.95±0.45)%,균현저고우치료지전적(1.46±0.42)L、(43.79±0.62)%、(52.64±0.45)%,이급대조조치료지후적(1.46±0.67)L、(46.28±0.62)%、(56.74±0.51)%;관찰조치료지후적6-MWD위(226.08±18.5)m,현저대우치료지전적(180.55±16.8)m,이급대조조치료지후적(185.25±19.9)m;호흡곤난적평분위(2.05±0.62)분,균현저저우치료지전적(3.04±0.24)분,이급대조조치료지후적(2.97±0.58)분,차이균유통계학의의(균P<0.05)。치료12주지후,관찰조유2례구인부불괄,1례두통,1례심계;대조조1례구인부불괄,1례심계。2조차이무통계학의의。결론신필가도보약물여맹로사특약물련용,가이치료은정기적중중도COPD질병,료효교위현저,치득림상추천。
Objective To study the clinical effect of budesonide and formoterol fum arate powder for inhalation combined montelukast for treatment of stable phase of moderate and severe COPD. Methods 86 patients with diagnosed stable phase of moderate and severe COPD were randomly divided into observation group and control group both with 43 cases. Clinical effects and Adverse reactions conditions of the 2 groups were compared. Results FEV1, FEV 1%and FEV 1/FVC of observation group after treatment were respectively(1.59±0.55)L,(56.33±0.65)%and (61.95±0.45)%which were all obviously higher than before treatment(1.46±0.42)L,(43.79±0.62)%and(52.64±0.45)%and control group after treatment(1.46±0.67)L,(46.28±0.62)% and(56.74±0.51)%; 6-MWD was(226.08±18.5)m which was obviously larger than before treatment (180.55±16.8)m, and than control group after treatment(185.25±19.9)m;dyspnea score was(2.05±0.62)which was obviously lower than before treatment(180.55±16.8)m and than control group after treatment(2.97±0.58)(P<0.05). After 12 weeks of treatment, there were 2 oropharyngeal discomfort, 1 headache and 1 palpitation in observation group while 1 oropharyngeal discomfort and 1 palpitation in control group. Conclusion Budesonide and formoterol fum arate powder for inhalation combined montelukas for treatment of stable phase of moderate and severe COPD has a significant clinical effect and is worth of being recommended clinically.